Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non small cell lung cancer, Stage IIIB or Stage IV~* One and only 1 prior platinum-based chemotherapy~* No other uncontrolled concurrent illness~* Use of highly effective birth control methods in males or females with reproductive potential~Exclusion Criteria:~* Previous participation in another trial within the last 4 weeks~* Surgery within 10 days prior to the start of study treatment~* Brain metastases~* Confirmed diagnosis of infection with the human immunodeficiency virus (HIV)~* Current treatment with warfarin sodium (Coumadin) or similar anticoagulation medication~* Breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).